Skip to main content
. 2018 Mar 6;319(9):883–895. doi: 10.1001/jama.2018.0154

Figure 2. Cumulative Incidence of Prostate Cancer Detection and Mortality in the Single Prostate-Specific Antigen Testing Intervention Group vs Standard Practice (Control).

Figure 2.

Y-axis shown in blue indicates range from 0 to 8 events per 1000 men. For part A, the median follow-up was 10.03 years (interquartile range [IQR], 8.80 to 11.50) for the intervention group vs 9.92 years (IQR, 8.74 to 10.93) for the control group (crude rate difference, −0.01 per 1000 person-years; 95% CI, −0.05 to 0.02). For part B, the median follow-up was 9.85 years (IQR, 8.61 to 11.43) for the intervention group vs 9.82 years (IQR, 8.67 to 10.92) for the control group (crude rate difference, 0.65 per 1000 person-years; 95% CI, 0.52 to 0.78).

aDefined as definite, probable, or intervention-related prostate cancer death as determined by an independent cause of death committee.